




# The Journal of Clinical Immunology, “Moving On Up”: Its Impact on the Field of Inborn Errors of Immunity

Vincent R. Bonagura<sup>1,2</sup> · Jean Laurent Casanova<sup>3,4</sup>

Received: 9 September 2023 / Accepted: 19 September 2023 / Published online: 9 January 2024  
© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2023

We recently received our 2022 Impact Factor (IF), which once again has increased, now at 9.1. While we are well aware that the IF is only one of the many imperfect quantitative indicators of a scientific journal’s impact, we are pleased to see that this increase is accompanied by an increase in the number of submissions, downloads, and citations. More importantly, we are delighted to see an increase in both the scientific quality and geographical diversity of the papers we published. This attests to the extraordinary growth of this field, which has had a significant impact on an increasing number of medical disciplines.



Indeed, since March 11, 2013, when we took over the reins of the *Journal*, our vision had several components. The first was to make the *Journal* the International Journal of Inborn Errors of Immunity. Next, we revamped the Associate Editor and the Editorial Boards to include international leaders in research and clinical care of patients with inborn errors of immunity. These leaders in the field selected outstanding reviewers for manuscripts they handled and provided cutting-edge and timely reviews of all manuscripts submitted for publication in the *Journal*. With their help, we were able to substantially shorten the turnaround time for all reviews of manuscripts submitted for publication. Last, we developed different venues for reader and author communication in the field of inborn errors of immunity (editorials, reviews, articles, letters).

These efforts clearly paid off as shown in the steady increases in the *Journal*’s impact factor and the number of citations made each year since we took over the leadership of the *Journal*. These achievements are in large part attributable to the outstanding Associate Editors and the Editorial Board members the *Journal* had the good fortune to attract and retain over the past 10 years. We warmly thank them, as well as the many other referees and trusting authors. Of course, we also thank our readers who study and care for patients with inborn errors of immunity worldwide.

In June 2023, we invited the leadership of most, if not all, of the leading international societies in the field of inborn errors of immunity to join us in Paris. We discussed how to better connect these societies with the journal and how this effort could further foster the development of the field. We and the societies involved are pursuing this conversation, and we will keep you posted on our progress. We want to thank Takeda Pharmaceutical Company, CSL-Behring, and ADMA for their generous support that enabled this important and successful meeting to take place.

✉ Vincent R. Bonagura  
vbonagura@northwell.edu

<sup>1</sup> The Feinstein Institute for Medical Research, Zucker School of Medicine at Hofstra, Hempstead, NY, USA

<sup>2</sup> Steven and Alexandra Cohen Children’s Medical Center, Northwell Health, New York, NY, USA

<sup>3</sup> The Rockefeller University, New York, NY, USA

<sup>4</sup> Necker Hospital for Sick Children, Paris, France

Last, we again thank our outstanding Associate and Editorial Boards, our excellent reviewers who have provided quick and cutting-edge, insightful reviews for authors who submit their manuscripts to the *Journal* for publication, and our authors and readers who study and care for patients with inborn errors of immunity. Together, they have made these

achievements possible and have helped us make the *Journal of Clinical Immunology* the success it is.

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.